DIM-C-pPhCO2Me

DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK) . DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research[1][2][3][4][5].

Product Specifications

CAS Number

[151358-48-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; DAPK; Isocitrate Dehydrogenase (IDH) ; Nuclear Hormone Receptor 4A/NR4A; PERK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/DIM-C-pPhCO2Me.html

Purity

99.47

Solubility

DMSO : ≥ 125 mg/mL

Smiles

COC(C1=CC=C(C(C2=CNC3=C2C=CC=C3)C4=CNC5=C4C=CC=C5)C=C1)=O

Molecular Formula

C25H20N2O2

Molecular Weight

380.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10 (6) :e0128308.|[2]Hedrick E, et al. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocr Relat Cancer. 2015 Oct;22 (5) :831-40.|[3]Lacey A, et al. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Mol Cancer Ther. 2018 Dec;17 (12) :2756-2766.|[4]Lacey A, et al. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1. Cancer Res. 2017 Feb 1;77 (3) :732-741.|[5]Cui P, et al. Deficiency of the Transcription Factor NR4A1 Enhances Bacterial Clearance and Prevents Lung Injury During Escherichia Coli Pneumonia. Shock. 2019 Jun;51 (6) :787-794.